J. Goldman & Co’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

J. Goldman & Co’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-758,431	Closed	-$1.68M	–	528
2023 Q2	$1.68M	Sell	758,431 -157,070	-17%	-$326K	0.06%	219
2023 Q1	$2.33M	Buy	915,501 +865,126	+1,717%	+$1.71M	0.09%	200
2022 Q4	$94.2K	Sell	50,375 -408,625	-89%	-$1.02M	﹤0.01%	327
2022 Q3	$1.18M	Buy	459,000 +438,647	+2,155%	+$1.09M	0.06%	245
2022 Q2	$39K	Sell	20,353 -1,036,278	-98%	-$2.26M	﹤0.01%	325
2022 Q1	$3.14M	Buy	+1,056,631	New	+$3.98M	0.14%	168
2020 Q3	–	Sell	-83,334	Closed	-$435K	–	413
2020 Q2	$435K	Sell	83,334 -104,421	-56%	-$464K	0.03%	226
2020 Q1	$591K	Buy	187,755 +87,755	+88%	+$324K	0.07%	159
2019 Q4	$403K	Sell	100,000 -58,650	-37%	-$203K	0.03%	224
2019 Q3	$685K	Buy	+158,650	New	+$634K	0.05%	205

J. Goldman & Co's PRTK Position: Q3 2023 in Review

J. Goldman & Co sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 758,431 shares — an estimated $1.68M sold.

J. Goldman & Co first reported a position in PRTK in Q3 2019 and held it in 10 quarters. The position peaked at $3.14M in Q1 2022. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.

J. Goldman & Co reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
J. Goldman & Co sold 758,431 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $1.68M.
J. Goldman & Co first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2019 and held it in 10 quarters.
J. Goldman & Co's Paratek Pharmaceuticals, Inc. position peaked at $3.14M in Q1 2022.
0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.

Based on J. Goldman & Co's 13F filing for Q3 2023, filed 14 Nov 2023.